Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Prostate Cancer|Hormone Sensitive Prostate Cancer|Metastatic Tumor
DRUG: Docetaxel|DRUG: Apalutamide Oral Tablet|DRUG: Enzalutamide Oral Tablet|DRUG: Abiraterone acetate tablets|DRUG: Darolutamide Oral Tablet|RADIATION: radiotherapy|DRUG: Triptorelin
progression free survival, the projected rate over the time of patients without progressive disease, From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
overall survival, the projected rate over the time of alive patients, From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
rate of patients with an objective response, rate of patients who experienced a reduction of at least 30% of measurable lesions, through study completion, an average of 2 year
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice